Previous 10 | Next 10 |
2024-04-30 08:24:49 ET More on pre-market losers & stocks. Biodexa shares rally 126% on rapamycin licensing deal NewGenIvf signs non-binding term sheet for potential reverse merger with European Wellness Investment Holdings Seeking Alpha’s Quant Rating on ...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: ȁ...
2024-04-29 08:36:50 ET More on premarket gainers & stock Diving Into Deciphera Pharmaceuticals Fulton Financial Corporation (FULT) Q1 2024 Earnings Call Transcript Fulton Financial Corporation 2024 Q1 - Results - Earnings Call Presentation Fulton Financia...
2024-04-10 13:29:22 ET Summary Mesoblast Limited has been on a major run recently as its cell therapy candidate is back on track towards potential approval. The company has some upcoming potential catalysts in the quarters ahead and is advancing its pipeline on several fronts. ...
2024-04-07 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-03 08:12:40 ET More on Pre-market losers & stocks. Emeren Group Ltd. (SOL) Q4 2023 Earnings Call Transcript Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript Mesoblast Limited 2024 Q2 - Results - Earnings Call Presentation Acorda falls 59%...
2024-04-02 10:45:02 ET Kinross Gold Corp. (KGC) KGC is trading UP for the last 5 days, and it at trading at $6.24 with volume of 4,912,280 and a one day change of $0.08 (1.22%). Kinross Gold Corp. has a 52-week low of 4.32 and a 52-week high of $6.34. The business's 50-day moving av...
2024-04-01 12:57:59 ET More on Mid-day movers & stocks. Meta Materials total Q4 revenue up 55% y/y Meta Materials announces $1M civil penalty to settle SEC investigation Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for...
Mesoblast Limited (NASDAQ: MESO) is one of today's top gainers. The company's shares have moved 30.62% on the day to $6.55. Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, ...
2024-04-01 10:00:18 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
2024-06-27 02:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...